Last reviewed · How we verify
Pharmaceutical fresh frozen plasma
Pharmaceutical fresh frozen plasma, marketed by Fundación Cardioinfantil Instituto de Cardiología, holds a position in the therapeutic plasma market. A key strength is the protection of its core composition through a patent expiring in 2028. The primary risk is the lack of disclosed revenue data, which may limit insights into market performance and financial stability.
At a glance
| Generic name | Pharmaceutical fresh frozen plasma |
|---|---|
| Sponsor | Fundación Cardioinfantil Instituto de Cardiología |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study Assessing Efficacy of Plasmatherapy in Septic Shock-induced Coagulopathy: Feasibility Study (NA)
- Exploiting Heterogeneity in Hormone Therapy Response to Reveal Early Determinants of Drug Resistance in Advanced PCa
- Efficacy of Prothrombin Complex Concentrate Reducing Perioperative Blood Loss in Cardiac Surgery (PHASE4)
- A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) (PHASE2, PHASE3)
- Study of Protection And Repair of Endothelial-glycocalyx in Sepsis (PHASE2)
- Enhancing Hepatitis C Testing and Treatment Among People Who Inject Drugs Attending Needle and Syringe Programs (NA)
- Randomized Control Study in REsuscitation of SEpsis Trial (PHASE4)
- Effect of Giving Reduced Fluid in Children After Trauma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: